Atovaquone is part of the antimalarial drug combination atovaquone-proguanil (Malarone) and inhibits the cytochrome bc1 complex of the electron transport chain in Plasmodium spp. Molecular modelling showed that amino acid mutations are clustered around a putative atovaquone-binding site resulting in a reduced binding affinity of atovaquone for plasmodial cytochrome b, thus resulting in drug resistance.
Department of Medical Laboratory Technology, Faculty of Health Sciences, Haramaya University, Haramaya, Ethiopia. tamiratgw2002@yahoo.com <tamiratgw2002@yahoo.com>
